Genomics-based resistome analysis revealed endogenous adenosine kinase levels as a chief determinant of specificity for a novel nucleoside analog lymphoma inhibitor

Utthara Nayar, Jonathan Reichel, Jouliana Sadek, Denise Hernandez-Hopkins, Gunkut Akar, Hufeng Zhou, Michelle A. Sahai, Peter Barelli, Ilaria Guasparri, Jennifer Totonchy, Duane Hassane, Shizuko Sei, Robert H. Shoemaker, J. David Warren, Olivier Elemento, Kenneth M. Kaye, Ethel Cesarman

Research output: Contribution to journalArticle

Original languageEnglish
JournalClinical Cancer Research
Volume75
DOIs
Publication statusPublished - 1 Aug 2015

Cite this

Nayar, U., Reichel, J., Sadek, J., Hernandez-Hopkins, D., Akar, G., Zhou, H., Sahai, M. A., Barelli, P., Guasparri, I., Totonchy, J., Hassane, D., Sei, S., Shoemaker, R. H., Warren, J. D., Elemento, O., Kaye, K. M., & Cesarman, E. (2015). Genomics-based resistome analysis revealed endogenous adenosine kinase levels as a chief determinant of specificity for a novel nucleoside analog lymphoma inhibitor. Clinical Cancer Research, 75. https://doi.org/10.1158/1538-7445.AM2015-4496